South Korean pharmaceutical company GC Biopharma plans to acquire California-based ABO Holdings, expanding its foothold in the US blood products market after gaining FDA approval for its immune deficiency treatment.
The deal will give GC Biopharma control of six blood banks across New Jersey, Utah, and California, with two additional facilities under construction in Texas. The acquisition follows the company’s successful launch of Aliglobo, its intravenous immunoglobulin treatment, in the US market earlier this year.
The purchase price wasn’t disclosed in the regulatory filing. The transaction represents a vertical integration strategy for GC Biopharma, connecting raw material sourcing with production and distribution of plasma-derived therapies.
ABO Holdings’ planned expansion to eight collection centers by 2026 could help GC Biopharma reduce its reliance on external plasma suppliers. The global plasma proteins market faces ongoing supply constraints and rising raw material costs.
The company’s management says the deal positions it to compete with top-tier blood product manufacturers, though it will need to navigate a competitive US market dominated by established players like CSL Behring and Takeda Pharmaceutical.
Aliglobo received FDA approval in December 2023 for treating primary humoral immunodeficiency, a condition where patients lack antibodies to fight infections.
